Noble Financial Initiates a Buy Rating on TrovaGene (TROV)


Noble Financial analyst Ahu Demir initiated coverage with a Buy rating on TrovaGene (TROV) on January 7 and set a price target of $5.20. The company’s shares closed yesterday at $0.53, close to its 52-week low of $0.50.

Currently, the analyst consensus on TrovaGene is a Moderate Buy with an average price target of $3.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.70 and a one-year low of $0.50. Currently, TrovaGene has an average volume of 1.07M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts